ModifiedKaiser PermanentePolicy N/A

Clinical Review Criteria High-Frequency Chest Wall Oscillation Devices (HFCWO)

Clinical review criteria governing medical necessity and coverage considerations for HFCWO airway clearance systems (e.g., Vest, ABI/ThAIRapy, Volara) for Kaiser Permanente Washington members; intended for providers requesting rental or purchase and utilization decisions.

Policy Summary

PayerKaiser Permanente

PolicyHigh-Frequency Chest Wall Oscillation Devices (HFCWO) — Clinical Review Criteria

Policy CodePolicy N/A

Change TypeCoding additions and criteria revision

Effective DateDec 13, 2000

Next Review DateN/A

Key ActionObtain prior authorization and submit the last 6 months of clinical notes to demonstrate diagnosis, specialist management, prior therapy compliance, and rental-trial results.

SourceLink

POLICY UPDATE CHANGES

Added HCPCS codes E0469 and A7021 for BiWaze Clear System and Volara system to the coding section.

MPC approved criteria updates for HFCWO devices to better align with current medical evidence 2025.

Updated Medicare coverage links and references and clarified Medicare vs Non‑Medicare stances for specific systems.

MultipleDevices discussed

InsufficientEvidence conclusion

Last 6 monthsDocumentation required

07/17/2025

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for HFCWO Devices

Non-Medicare Medical Necessity Criteria

Covered when ALL of the following are met for Non‑Medicare members (as stated):

Overall: Member has a diagnosis of cystic fibrosis and is managed by a pulmonologist

From Non‑Medicare criteria pathway A

Therapy compliance: Has demonstrated compliance with chest physical therapy and flutter device at least twice daily (when age appropriate)

From Non‑Medicare criteria pathway A

Pulmonologist recommendation: HFCWO has been recommended by the pulmonologist

From Non‑Medicare criteria pathway A

Alternative pathway B – qualifying conditions: Member meets ALL of the following with one of these conditions: bronchiectasis confirmed by CT with clinical history (including daily productive cough for at least 6 continuous months or frequent exacerbations requiring antibiotics) OR a qualifying neuromuscular disorder (examples include acid maltase deficiency, anterior horn cell diseases including ALS, hereditary muscular dystrophy, multiple sclerosis, myotonic disorders, other myopathies, post‑polio quadriplegia)Daily productive cough for at least 6 continuous months

From Non‑Medicare criteria pathway B.i and listed neuromuscular disorders

Failure of standard treatments: Well‑documented failure of standard treatments to adequately mobilize retained secretions, including chest physical therapy and flutter device at least twice daily (when age appropriate); a pattern of hospitalizations at least annually or more; and significantly deteriorating clinical condition

From Kaiser‑specific criteria

Specialist care and trial: Be under the care of a pulmonologist AND have had a rental trial to confirm compliance before purchase

From Kaiser‑specific criteria

Coverage stance groups

Medicare & Non‑Medicare coverage summaries provided in the document:

Medicare coverage for vest systems: High frequency chest wall oscillation system vests (HCPCS A7025, A7026, E0480, E0483) are considered medically necessary when criteria in the applicable policy statements listed above are met.

See applicable policy statements and Medicare coverage links

BiWaze Clear & Volara (Medicare): BiWaze Clear System and VolaraTM System are considered medically necessary for Medicare members when criteria in the applicable policy statements listed above are met.

Medicare: refer to applicable policy statements

BiWaze Clear & Volara (Non‑Medicare): Non‑Medicare: BiWaze Clear System and VolaraTM System are listed as not medically necessary / experimental, investigational, or unproven for specified HCPCS codes (e.g., A7021, E0469) as noted in the policy.

Codes and stances may be updated; verify pre‑authorization and coding

The Volara™ System (OLE) and related oscillation/lung‑expansion therapies are considered unsupported for routine use when peer‑reviewed evidence is insufficient. Specifically, the document states there is insufficient evidence in the published literature to show that the Volara/OLF service or therapy is as safe or provides better long‑term outcomes than standard therapies, and therefore does not meet Kaiser Permanente Medical Technology Assessment Committee (MTAC) criteria for those indications. Additionally, use of high‑frequency chest wall oscillation (HFCWO) for neuromuscular deficiency is noted to have no empirical evidence demonstrating safety and effectiveness and likewise does not meet MTAC criteria.

For Non‑Medicare members, the policy lists the BiWaze Clear System and Volara System as Not medically necessary / experimental, investigational, or unproven for the specified HCPCS codes. The document explicitly names HCPCS codes such as A7021 and E0469 in the Non‑Medicare stance and cautions that deleted or out‑of‑effect codes may not be covered; it also directs providers to verify authorization requirements via the Pre‑authorization Code Check.

The policy summarizes MTAC and external evidence reviews concluding that several devices and indications lack adequate evidence. The use of the ThAIRapy/ABI (ABI) Vest for cystic fibrosis is judged to have insufficient empirical evidence and therefore does not meet MTAC criteria. Similarly, HFCWO for neuromuscular disease is unsupported by adequate studies and is not recommended under MTAC criteria. The Volara and Maximus systems have no direct safety/effectiveness trials identified; limited and biased studies of predecessor systems (e.g., MetaNeb) do not provide sufficient support for these devices in the populations under consideration.

Non‑Medicare coverage language lists specific HCPCS codes as Not medically necessary / experimental, investigational, or unproven, including A7021 (supplies and accessories for lung expansion/airway clearance/high frequency oscillation and nebulization devices) and E0469 (HFCWO system vest, replacement for use with patient‑owned equipment). The policy also notes that codes may not be all‑inclusive and that deleted or inactive codes may not be covered; providers should confirm pre‑authorization requirements by plan type.

Coding and Reimbursement

Medicare local coverage referencesmixed

L33785	Local Coverage Determination: High Frequency Chest Wall Oscillation Devices
A52494	Local Coverage Article: High Frequency Chest Wall Oscillation Devices

Medicare & Non‑Medicare listed codesHCPCSCovered

A7025	High frequency chest wall oscillation system vest; replacement for use with patient-owned equipment_each
A7026	High frequency chest wall oscillation system vest; replacement for use with patient-owned equipment_each
E0480	High frequency chest wall oscillation system vest
E0483	High frequency chest wall oscillation system vest

Codes noted for BiWaze Clear System & VolaraHCPCSCovered

A7021	Supplies and accessories for lung expansion airway clearance, continuous high frequency oscillation,and nebulization device (e.g, handset_nebulizer kit,biofilter)
E0469	High frequency chest wall oscillation system vest, replacement for use with patient-owned equipment_each

Duration of productive cough for bronchiectasis criteria

Bronchiectasis productive cough durationDaily productive cough for at least 6 continuous months

Alternate bronchiectasis indicatorFrequent (more than yearly) exacerbations requiring antibiotic therapy

Imaging confirmationBronchiectasis must be confirmed by high-resolution, spiral, or standard CT scan

Policy revision date

Policy revision date07/17/2025

Medical Policy Committee updateMPC approved criteria updates for HFCWO devices on 02/04/2025

Provider Actions, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior authorization is required for HFCWO devices. Approvals depend on meeting the applicable clinical criteria (e.g., cystic fibrosis, bronchiectasis with documented criteria, or qualifying neuromuscular disorders) and documented management by a pulmonologist when required.

Prior authorization required — verify via plan-specific Pre-authorization Code Check.
Medicare and Non‑Medicare: devices (e.g., A7025, A7026, E0480, E0483) are considered medically necessary when criteria are met; BiWaze Clear and Volara: Medicare coverage follows the same applicable criteria.

Step Therapy

Step Therapy / Trial Requirements

Members must demonstrate prior compliance with conservative airway clearance measures before HFCWO is authorized. Failure to document trials of required therapies is a common reason for denial.

Step/trial requirement: Documented use of chest physical therapy and a flutter device at least twice daily (when age appropriate).

Background and Evidence Summary

High‑frequency chest wall oscillation (HFCWO) is a noninvasive airway clearance method that uses an inflatable vest coupled to an air‑pulse generator to create rapid, small, repeated chest wall compressions—typically in the range of 5–20 Hz—to mobilize airway secretions. The document emphasizes that HFCWO has most evidence in cystic fibrosis and other obstructive airway diseases, but that evidence for some indications (notably neuromuscular disorders) is limited, with small sample sizes, short follow‑up, and methodological limitations identified by MTAC and external reviews.

Device Definitions

VestTM Airway Clearance System

VestTM componentsInflatable non-stretch vest that covers the thorax; large-bore tubing; air-pulse generator

MechanismGenerator creates pressure to inflate/deflate the vest transmitting high-frequency (5–20 Hz) pressure impulses to the thorax

Typical treatmentA typical treatment may last 20–30 minutes consisting of periods of compression separated by huff coughs

Volara System (OLE) intended therapies

Intended therapiesProvides oscillation, lung expansion, PEP/CPEP/CHFO, and aerosolized medication delivery

Use settingsIntended for hospitalized and home use